NovoCure (NVCR) Non Operating Interest Expenses (2014 - 2022)

NovoCure has disclosed Non Operating Interest Expenses across 9 years of filings, most recently posting $2.2 million for Q2 2022.

• In Q2 2022, Non Operating Interest Expenses rose 137.02% year-over-year to $2.2 million; the TTM figure through Jun 2022 stood at $8.1 million (down 25.31% YoY), while the FY2021 annual figure was $7.7 million, down 37.05% from the prior year.
• Non Operating Interest Expenses came in at $2.2 million for Q2 2022 at NovoCure, up from $1.7 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $4.9 million in Q1 2018 to a low of $940000.0 in Q2 2021.
• Average Non Operating Interest Expenses over 5 years is $2.5 million, with a median of $2.4 million recorded in 2018.
• Year-over-year, Non Operating Interest Expenses slumped 64.08% in 2021 and soared 137.02% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at $2.2 million in 2018, then declined by 19.21% to $1.7 million in 2019, then surged by 87.22% to $3.3 million in 2020, then tumbled by 33.43% to $2.2 million in 2021, then gained by 2.44% to $2.2 million in 2022.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2.2 million in Q2 2022, $1.7 million in Q1 2022, and $2.2 million in Q4 2021.